Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study
- PMID: 39640976
- PMCID: PMC11617145
- DOI: 10.3389/fmed.2024.1481051
Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study
Abstract
Purpose: Chronic hepatitis B (CHB) and fatty liver disease (FLD) are common chronic liver diseases, both of which can progress to advanced liver diseases with poor outcome. However, it remains controversial whether the presence of FLD aggravates the disease severity of CHB patients.
Patients and methods: All consecutive outpatients who were diagnosed with CHB at our department between March 1, 2021 and September 30, 2023 were retrospectively screened. They were divided into FLD and non-FLD groups. Liver function parameters and non-invasive indicators of liver fibrosis, including liver stiffness measurement (LSM) value, fibrosis-4 index (FIB-4) score, and aspartate aminotransferase to platelet ratio index (APRI) score, were compared between the two groups. Subgroups analyses were performed in HBeAg-positive, HBeAb-positive, HBV DNA > 10 IU/mL, mild FLD, and moderate/severe FLD patients.
Results: Overall, 201 CHB patients were included, of whom 76 (37.81%) had FLD. In the overall analyses, CHB patients with FLD had a significantly higher alanine aminotransferase (ALT) (47.04 ± 53.28 vs. 32.95 ± 35.10, p = 0.003) than those without FLD, but there was no significant difference in the LSM value (7.79 ± 5.16 vs. 8.19 ± 4.99, p = 0.508), FIB-4 score (1.13 ± 0.75 vs. 1.28 ± 0.99, p = 0.679), and APRI score (0.41 ± 0.46 vs. 0.36 ± 0.47, p = 0.535) between CHB patients with and without FLD. The above-mentioned statistical results in all subgroup analyses were nearly consistent with those in the overall analyses.
Conclusion: FLD may intensify abnormal liver function reflected by increased ALT level in CHB patients, but not influence the progression of liver fibrosis.
Keywords: chronic hepatitis B; effect; fatty liver disease; fibrosis; prevalence.
Copyright © 2024 Fang, Yin, Zhao, Wang, Li, Shang, Li, Gao, Méndez-Sánchez and Qi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures
Similar articles
-
Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B.JAMA Netw Open. 2022 Jun 1;5(6):e2216485. doi: 10.1001/jamanetworkopen.2022.16485. JAMA Netw Open. 2022. PMID: 35696167 Free PMC article.
-
Gamma-Glutamyl Transpeptidase-to-Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease.J Clin Lab Anal. 2022 Aug;36(8):e24596. doi: 10.1002/jcla.24596. Epub 2022 Jul 9. J Clin Lab Anal. 2022. PMID: 35808928 Free PMC article.
-
Assessment of liver fibrosis by transient elastography and multi-parameters model in young children with chronic hepatitis B virus infection.BMC Infect Dis. 2022 Feb 18;22(1):160. doi: 10.1186/s12879-022-07142-7. BMC Infect Dis. 2022. PMID: 35180839 Free PMC article.
-
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease.Hepatol Res. 2023 Mar;53(3):184-195. doi: 10.1111/hepr.13854. Epub 2022 Nov 21. Hepatol Res. 2023. PMID: 36317959
-
Treatment of chronic hepatitis B: case selection and duration of therapy.J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. doi: 10.1046/j.1440-1746.2002.02767.x. J Gastroenterol Hepatol. 2002. PMID: 11982721 Review.
Cited by
-
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B.PLoS One. 2025 May 27;20(5):e0324897. doi: 10.1371/journal.pone.0324897. eCollection 2025. PLoS One. 2025. PMID: 40424405 Free PMC article.
References
-
- Committee of Hepatology CRHA, Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver and Metabolism, Chinese Society of Endocrinology, Chinese Medical Association . Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition). Zhonghua Gan Zang Bing Za Zhi. (2019) 27:748–53. doi: 10.3760/cma.j.issn.1007-3418.2019.10.003 - DOI - PubMed
LinkOut - more resources
Full Text Sources